References
- KolbeckRKozhichAKoikeMMEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity functionJ Allergy Clin Immunol201012561344135320513525
- LötvallJPulleritsTTreating asthma with anti-IgE or anti-IL5Curr Pharm Des199951075777010529435
- LavioletteMGossageDLGauvreauGEffects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophiliaJ Allergy Clin Immunol201313251086109623866823
- BusseWWKatialRGossageDSafety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthmaJ Allergy Clin Immunol201012561237124420513521
- BleeckerERFitzGeraldJMChanezPEfficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialLancet2016388100562115212727609408
- FitzGeraldJMBleeckerERNairPBenralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialLancet2016388100562128214127609406
- FASENRA™ (benralizumab) injection, for subcutaneous use [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2017 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdfAccessed July 11, 2018
- FASENRA™ (benralizumab) injection, for subcutaneous use [summary of product characteristics]Wilmington, DEAstraZeneca Pharmaceuticals LP2018 Available from: http://ec.europa.eu/health/documents/community-register/2018/20180108139598/anx_139598_en.pdfAccessed July 11, 2018
- AstraZenecaFasenra receives approval in Japan [press release] Astra-Zeneca2018 Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/fasenra-recieves-approval-in-japan-19012018.htmlAccessed July 11, 2018
- PesekRLockeyRVaccination of adults with asthma and COPDAllergy20116612531
- VasileiouESheikhAButlerCEffectiveness of influenza vaccines in asthma: a systematic review and meta-analysisClin Infect Dis20176581388139528591866
- EsnaultSKellyEAEssential mechanisms of differential activation of eosinophils by IL-3 compared to GM-CSF and IL-5Crit Rev Immunol201636542944428605348
- JacobsenEAHelmersRALeeJJLeeNAThe expanding role(s) of eosinophils in health and diseaseBlood2012120193882389022936660
- McMahanZHBinghamCO3rdEffects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseasesArthritis Res Ther201416650625587634
- SherACoffmanRLHienySCheeverAWAblation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouseJ Immunol199014511391139162123226
- FLULAVAL QUADRIVALENT (influenza vaccination) suspension for intramuscular injection [highlights of prescribing information]Research Triangle Park NCGlaxoSmithKline2013 Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM404086.pdfAccessed July 11, 2018
- HannounCMegasFPiercyJImmunogenicity and protective efficacy of influenza vaccinationVirus Res20041031–213313815163501
- HobsonDCurryRLBeareASWard-GardnerAThe role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesJ Hyg19727047677774509641
- LarattaCRWilliamsKVethanayagamDUlanovaMVliagoftisHA case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccineAllergy Asthma Clin Immunol2017132728596792